AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00003425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00003425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00003425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT02041507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation method.
Description: Air insufflation colonoscopy.
Study NCT02041507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion method.
Description: Water Immersion during insertion, air insufflation during withdrawal.
Study NCT02041507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange method.
Description: Water Exchange during insertion, air insufflation during withdrawal.
Study NCT03556163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified vertical internal mattress sutures + MWF surgery.
Description: Modified vertical internal mattress sutures were given after modified Widman flap surgery.
Study NCT03556163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple loop interrupted sutures + MWF surgery.
Description: Simple loop interrupted sutures were given after modified Widman flap surgery.
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 9 mg tablet once a day followed by PET scan in approximately 2 hours
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 6 mg tablet once a day followed by PET scan in approximately 2 hours
Study NCT00934635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET Scan
Description: PET Scan
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 4 mg tablet once a day followed by PET scan in approximately 24 hours
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 4 mg tablet once a day followed by PET scan in approximately 2 hours
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 6 mg tablet once a day followed by PET scan in approximately 2 hours
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 6 mg tablet once a day followed by PET scan in approximately 24 hours
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: 6 mg tablet once a day followed by PET scan in approximately 24 hours
Study NCT00934635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 9 mg tablet once a day followed by PET scan in approximately 24 hours
Study NCT04062110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plaster cast
Description: Closed Reduction of Fracture and Application of Plaster Cast
Study NCT03540108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum ECGC 13110402
Description: The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
Study NCT00471965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + 5-Fluorouracil/Leucovorin
Description: Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks
Study NCT00471965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
Study NCT02214472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Study NCT02214472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02653820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Study NCT00634504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucarpidase, high-dose methotrexate, leucovorin
Description: single intravenous dose
Study NCT00634504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose methotrexate, leucovorin
Description: standard of care, leucovorin every 6 hours
Study NCT01534793 — intervention group
Intervention type: PROCEDURE
Intervention: Holmium Laser Enucleation of the Prostate (HoLEP)
Description: Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
Study NCT03520530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Guard
Description: Patient will wear mouth guard while pushing in the second stage of labor
Study NCT04657913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold water spray application
Description: It will be sprayed into the mouth of patients every hour.
Study NCT04657913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold saline spray application
Description: It will be sprayed into the mouth of patients every hour.
Study NCT02696616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655088
Study NCT02696616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03540108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Maltodextrin
Description: Please see intervention description above.
Study NCT05331560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation (TPS)
Description: A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second).
Study NCT02563314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation - Normoxia
Description: Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
Study NCT02563314 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive mechanical ventilation - Controlled hypoxemia
Description: Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
Study NCT00498914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: Continuous IV infusion
Study NCT04811742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bathing
Description: immerson bathing and showering
Study NCT03749759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: A biofeedback measurement will be carried out during cataract surgery of both eyes
Study NCT02967653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
Study NCT02967653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
Study NCT04365712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezoelectric tool
Study NCT04365712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillating Saw
Study NCT01276639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg oral BID, Continuous treatment for 52 Weeks
Study NCT01276639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg oral BID, Continuous treatment for 52 Weeks
Study NCT01276639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/CP-690,550
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Study NCT01276639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/CP-690,550
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Study NCT03868033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
Study NCT03868033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
Study NCT00390767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiGeneAngio
Description: Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
Study NCT03647657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PP-F11N
Description: Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient
Study NCT03647657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacuitril
Description: Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
Study NCT02568514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secure text messaging
Description: A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
Study NCT00566423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Venous and Arterial Blood draw samples; 6 Minute Walk test
Study NCT02423655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for deferred dialysis intervention
Description: Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
Study NCT02423655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm for routine dialysis intervention
Description: Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
Study NCT03835299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Intervention
Description: Coping information related to the fear that was identified by the participant will be presented via a computer tablet.
Study NCT00605124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee muscle exercises
Description: Home exercises three times a week, control every three months
Study NCT00605124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee muscle exercises
Description: Home exercises three times a week, control every three months
Study NCT02469623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dipole Density Mapping with AcQMap followed by ablation
Study NCT04690140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epithelialized free gingival graft
Description: The Epithelialized free gingival graft placed on the prepared bed.
Study NCT04690140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified coronally advanced tunnel technique
Description: Connective tissue graft placed under the prepared tunnel
Study NCT02836652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate II (HMII)
Description: Left Ventricular Assist Device
Study NCT02836652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII)
Description: Left Ventricular Assist Device
Study NCT02836652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: (INR Target 2.0-2.5, median 2.25, per standard of patient care)
Study NCT02836652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: (INR Target 2.0-2.5, median 2.25, per standard of patient care)
Study NCT02836652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid (ASA) therapy
Description: (81mg/day)
Study NCT01169948 — intervention group
Intervention type: RADIATION
Intervention: Computed tomography scan
Description: Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
Study NCT00587158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
Study NCT00587158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Avoidance Immune Suppression Protocol
Description: Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
Study NCT00587158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Corticosteroid Avoidance Immune Suppression Protocol
Description: Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
Study NCT01153867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Focused Therapy
Description: SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
Study NCT04033744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extraction of mandibular third molar
Description: After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
Study NCT04033744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extraction of mandibular third molar
Description: After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
Study NCT03741972 — intervention group
Intervention type: DRUG
Intervention: iSGTL2
Description: Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
Study NCT02938195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
Study NCT02938195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
Study NCT04115384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolin-R insulin
Description: Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
Study NCT03324243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: 66.7 mg/m2 three times a day (TID)
Study NCT03324243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day, intravenous infusions over 30 mins.
Study NCT03324243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m2/day, intravenous infusions over 1-3 hours.
Study NCT00250237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol 1mg twice daily during 72hours
Study NCT00250237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 1mg twice daily during 72hours
Study NCT00088140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDN-6556
Study NCT00088140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03573141 — intervention group
Intervention type: OTHER
Intervention: Physical Therapy
Description: Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
Study NCT03335735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-framed text message
Description: Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.
Study NCT03335735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed text message
Description: Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
Study NCT00496080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Description: Investigational transvaginal clamp inserted one time for 6 hours.
Study NCT04137913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical arts intervention
Description: A 6-week group music class that incorporates listening, theory, performance, and creation of music.
Study NCT03287999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombophilia screen
Description: Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
Study NCT03287999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Initiation pathway analysis
Description: Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
Study NCT00918177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP09004
Study NCT00918177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/Levodopa, immediate release